STAT+: Fulcrum study suggests improved efficacy for higher dose sickle cell pill
Fulcrum Therapeutics said Sunday that a higher dose of its experimental pill for sickle cell disease was more effective at inducing an alternative form of the oxygen-carrying molecule hemoglobin — boosting hopes